1. Application afukozilirovannogo anti-CD20-antibody to the fucose content of 60% or less of the total amount of oligosaccharides (sugars) at Asn297 for the manufacture of a medicament for treating cancer in combination with anti-VEGF-antitelom.2. Use according to claim 1, characterized in that the cancer is a CD20-expressing rakom.3. Use according to claim 1, characterized in that the CD20-expressing cancer is a B-cell non-Hodgkins lymphoma (NHL) .4. Use according to claim 1, characterized in that the anti-CD20-antibody is a humanized B-Ly1-antitelom.5. Use according to claim 1, characterized in that anti-VEGF-antibody is bevacizumab, B20 series antibody, or antibody G6.6 series. Use according to claim 1, characterized in that the anti-CD20-antibody is a humanized B-Ly1-antibody and said anti-VEGF-antibody or antibody is bevacizumab V20.7 series. Use according to any one of claims 1-6, characterized in that it is administered one or more additional other cytotoxic, chemotherapeutic or anticancer agent, or a compound or ionizing radiation, which enhances the effects of such agentov.8. A composition comprising the humanized B-Ly1-antibody which afukozilirovano with fucose content of 60% or less of the total amount of oligosaccharides (sugars) at Asn297, and bevacizumab or B20 series antibody for the treatment raka.9. A method for treating a patient suffering from cancer, by administering afukozilirovannogo anti-CD20-antibody to the fucose content of 60% or less of the total amount of oligosaccharides (sugars) at Asn297 in combination with anti-VEGF-antibody to a patient in need of such lechenii.10. A method according to claim 9, characterized in that the decree1. Применение афукозилированного анти-CD20-антитела с содержанием фукозы 60% или менее от общего количества олигосахаридов (сахаров) на Asn297 для изготовления лекарственного средства для лечения рака в комбинации с анти-VEGF-антителом.2. Применение по п.1, характеризующееся тем, что рак является CD20-экспресси
